Abbott Laboratories has lowered its full-year 2026 guidance following weaker-than-expected demand in its EP/CGM segments during the fourth quarter. The company plans a nutrition business spin-off, which could unlock growth in its MedTech, Diagnostic, and Pharmaceutical divisions, improve profit margins, and create a new S&P 500-eligible stock. Despite near-term challenges like balance sheet pressure from the EXAS acquisition and ongoing litigation, Abbott's stock trades below its five-year average, presenting a potential buying opportunity with expected growth acceleration and a possible dividend increase in 2027.
Abbott Laboratories trades at USD 103.58 on Pluang as of Oct 27, 2026 21:12 WIB, down 1.24% in one day. The stock's market cap stands at $181.48 billion, with a dividend yield of 2.4%. Pluang order activity shows more sellers than buyers, at 59% sell versus 41% buy, reflecting cautious investor sentiment.
Medtronic increased its quarterly dividend to $0.72 per share, marking a 1.4% raise and extending its dividend increase streak to 49 years. While this steady growth ensures a reliable 2.95% yield, it trails behind faster-growing peers like Abbott and...
Abbott Laboratories is rated a Buy due to strong growth in its medical devices and diagnostics segments, which now make up 70% of its revenue. The company’s recent acquisition of Exact Sciences has accelerated diagnostics growth. Abbott plans to spin...
Abbott announced results from the Beta-CORRECT study showing its Oncodetect test, using whole-genome sequencing, improves detection of molecular residual disease (MRD) in colorectal cancer patients after surgery. The test showed a 30% higher sensitiv...
